Atricure reports fourth quarter 2024 and full year 2024 financial results

Mason, ohio--(business wire)--atricure, inc. (nasdaq: atrc), a leading innovator in surgical treatments and therapies for atrial fibrillation (afib), left atrial appendage (laa) management and post-operative pain management, today announced fourth quarter 2024 and full year 2024 financial results. “2024 was another outstanding year at atricure, marked by continued progress on driving growth, improving profitability, and the introduction of several meaningful product launches across our key fran.
ATRC Ratings Summary
ATRC Quant Ranking